Toggle navigation
The UK Cystic Fibrosis Gene Therapy Consortium
News
About Us
About
About
About
Who are we
Consortium Timeline
Profiles of the Consortium Strategy Group
Frequently Asked Questions
All Trials Registered Initiative
Contact Details
About this Website
Mailform
Videos
Funding
Funding
Funding
Funding
Funding Overview
Flutterby FUNdraisers
The Cystic Fibrosis Trust
Just Gene Therapy
Cystic Fibrosis
CF
CF
CF
What is Cystic Fibrosis?
History of Cystic Fibrosis
Discovery of the CFTR Gene
What causes Cystic Fibrosis?
CFTR Protein Structure
Gene Therapy
Introduction to Gene Therapy
Why use Gene Therapy to Treat CF?
Other CF Gene Therapy Groups
Successful Applications of Gene Therapy
CF Gene Therapy Clinical Trials
Clinical Programme
Clinical
Clinical
Clinical
GL67A pGM169 - Our first clinical trial product
The Tracking Study
The Run In Study
Single Dose Clinical Trial (2009-2011)
Multi Dose Clinical Trial (2012-2014)
Multi Dose Clinical Trial Protocol
Public Meeting, 30 May 2015
Research
Nonviral Vector Development
Aerosol Delivery of Gene Transfer Vectors
Assay Development
Lentiviral Vector Development
Lentiviral Production
Publications
Journal Articles
Conference Presentations
Book Chapters
Public Presentations
Blog
Journal Articles
Conference Presentations
Book Chapters
Public Presentations
Current issues around LCI (Lung Clearance Index).
Davies JC
UK Cystic Fibrosis Conference, Manchester, 2015
Tweet
Other Abstracts by these authors
A clinical study to evaluate the safety and efficacy of pGM169/GL67A administered to the nose and lungs of individuals with cystic fibrosis.
Hyde SC et al.
The American Society of Gene and Cell Therapy Annual Conference (2010)
Safety and expression of a single dose of lipidmediated CFTR gene therapy to the upper and lower airways of patients with Cystic Fibrosis.
Davies G et al.
British Thoracic Society Winter Meeting (2011)